NO20092279L - Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter - Google Patents

Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter

Info

Publication number
NO20092279L
NO20092279L NO20092279A NO20092279A NO20092279L NO 20092279 L NO20092279 L NO 20092279L NO 20092279 A NO20092279 A NO 20092279A NO 20092279 A NO20092279 A NO 20092279A NO 20092279 L NO20092279 L NO 20092279L
Authority
NO
Norway
Prior art keywords
factor viia
anticoagulants
inhibitors useful
viia inhibitors
macrocyclic
Prior art date
Application number
NO20092279A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel L Cheney
Nicholas R Wurtz
Peter W Glunz
Xiaojun Zhang
Eldon Scott Priestley
Vladimir Ladziata
Brandon Parkhurst
Luciano Mueller
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20092279L publication Critical patent/NO20092279L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
NO20092279A 2006-12-20 2009-06-12 Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter NO20092279L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87086406P 2006-12-20 2006-12-20
US98446007P 2007-11-01 2007-11-01
PCT/US2007/088032 WO2008079836A2 (en) 2006-12-20 2007-12-19 Macrocyclic factor viia inhibitors useful as anticoagulants

Publications (1)

Publication Number Publication Date
NO20092279L true NO20092279L (no) 2009-08-31

Family

ID=39430763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092279A NO20092279L (no) 2006-12-20 2009-06-12 Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter

Country Status (12)

Country Link
US (1) US8420830B2 (enExample)
EP (1) EP2102176A2 (enExample)
JP (1) JP2010514681A (enExample)
AR (1) AR064471A1 (enExample)
AU (1) AU2007337025A1 (enExample)
CA (1) CA2673598A1 (enExample)
CL (1) CL2007003718A1 (enExample)
MX (1) MX2009006689A (enExample)
NO (1) NO20092279L (enExample)
PE (1) PE20081775A1 (enExample)
TW (1) TW200836735A (enExample)
WO (1) WO2008079836A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039506B2 (en) 2006-12-20 2011-10-18 Bristol-Myers Squibb Company Bicyclic lactam factor VIIa inhibitors useful as anticoagulants
IN2012DN05081A (enExample) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
ES2822130T3 (es) 2010-02-11 2021-04-29 Bristol Myers Squibb Co Macrociclos como inhibidores del factor XIa
CN102993065B (zh) * 2011-09-13 2015-07-29 中国科学院上海药物研究所 含手性叔丁基亚磺酰基的α-芳基氨基酸酯类化合物、其制备方法及用途
TWI633091B (zh) 2011-10-14 2018-08-21 Bristol-Myers Squibb Company 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
ES2716832T3 (es) * 2011-12-27 2019-06-17 Bio Pharm Solutions Co Ltd Compuestos carbamatos de fenilo para su uso en el alivio o el tratamiento del dolor y el dolor neuropático
EP2858977A1 (en) 2012-06-08 2015-04-15 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
PL2880026T3 (pl) * 2012-08-03 2017-08-31 Bristol-Myers Squibb Company Dihydropirydon P1 jako inhibitory czynnika XIA
SG11201500270RA (en) * 2012-08-03 2015-03-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
EP3008052A1 (en) * 2013-06-13 2016-04-20 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
NO2760821T3 (enExample) 2014-01-31 2018-03-10
BR112016015717B1 (pt) 2014-01-31 2023-04-04 Bristol-Myers Squibb Company Compostos macrociclos com grupos p2' heterocíclicos como inibidores do fator xia, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
CN114874222B (zh) * 2015-07-29 2025-06-06 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5866542A (en) 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
UA78232C2 (uk) 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
JP2006517589A (ja) 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
US7122559B2 (en) 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
ES2349428T3 (es) 2005-01-10 2011-01-03 Bristol-Myers Squibb Company Derivados de fenilglicinamida útiles como anticoagulantes.
EP1866822A4 (en) * 2005-03-03 2010-09-01 Burnham Inst Medical Research SCREENING PROCEDURE FOR PROTEIN KINASE B INHIBITORS USING VIRTUAL DOCKING APPARATUS AND COMPOSITIONS AND COMPOSITIONS DISCOVERED THEREFOR
ES2337831T3 (es) 2005-06-24 2010-04-29 Bristol-Myers Squibb Company Derivados de fenilglicinamida y piridilclicinamida utiles como agentes anticoagulantes.
PE20071132A1 (es) 2005-12-23 2007-12-14 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
WO2007103996A1 (en) 2006-03-09 2007-09-13 Bristol-Myers Squibb Company 2-(aryloxy)acetamide factor viia inhibitors useful as anticoagulants
US8039506B2 (en) 2006-12-20 2011-10-18 Bristol-Myers Squibb Company Bicyclic lactam factor VIIa inhibitors useful as anticoagulants

Also Published As

Publication number Publication date
CL2007003718A1 (es) 2008-07-11
US20100113488A1 (en) 2010-05-06
WO2008079836A4 (en) 2009-03-12
US8420830B2 (en) 2013-04-16
JP2010514681A (ja) 2010-05-06
MX2009006689A (es) 2009-06-30
TW200836735A (en) 2008-09-16
PE20081775A1 (es) 2008-12-18
AR064471A1 (es) 2009-04-01
EP2102176A2 (en) 2009-09-23
WO2008079836A2 (en) 2008-07-03
CA2673598A1 (en) 2008-07-03
WO2008079836A3 (en) 2009-01-15
AU2007337025A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
NO20092279L (no) Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
NO20092050L (no) Nye sulfonamidderivater som bradykininantagonister
NO20083434L (no) Benzamid- og heteroarenderivater
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20092049L (no) Nye fenylsulfamoylbenzamidderivater som bradykininantagonister
TNSN08407A1 (en) Organic compounds
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20054852L (no) GFAT inhibitorer
NO20081217L (no) Nye benzotiazolonderivater
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20080717L (no) Oksimderivat og fremgangsmate for fremstilling av dette
TW200833675A (en) Nicotinamide derivatives
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
NO20064077L (no) Kemokinreseptorantagonister
MX2008012332A (es) Tiazolil-dihidro-indazoles.
NO20092048L (no) Nye benzamidderivater som bradykininantagonister
NO20085107L (no) Spirosykliske nitriler som proteaseinhibitorer
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application